Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene
Revvity, Inc. (RVTY)
Company Research
Source: Business Wire
APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is valuable to assess a patient’s risk for side effects prior to the start of an anti-amyloid (beta) therapy in Alzheimer’s disease.“With the introduction of new disease-modifying drugs for treating Alzheimer’s, a new era of therapy has begun for this incurable disease. However, it has been found that patients taking these treatments with a certain form of the APOE gene have a significant risk for developing potentially life-threatening side effects, called ARIA, referring to edema or microbleedings in the brain,” explains Dr. Lars Komorowski, chief scientific officer of EUROIMMUN. “Being able to easily deter
Show less
Read more
Impact Snapshot
Event Time:
RVTY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVTY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVTY alerts
High impacting Revvity, Inc. news events
Weekly update
A roundup of the hottest topics
RVTY
News
- Revvity Broadens Relationship with Genomics England to Advance Genomics in the UKBusiness Wire
- Revvity to Present at 7th Annual Evercore ISI HealthCONx ConferenceBusiness Wire
- Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single CellsBusiness Wire
- Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent TransformationBusiness Wire
- Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at TD Cowen from $141.00 to $144.00. They now have a "buy" rating on the stock.MarketBeat
RVTY
Earnings
- 11/4/24 - Beat
RVTY
Sec Filings
- 11/19/24 - Form NPORT-P
- 11/14/24 - Form SC
- 11/8/24 - Form SC
- RVTY's page on the SEC website